A European Union research grant and a strong set of financial results drove the health and biotech newsflow on Monday, with Frontier IP's portfolio company securing funding to push Parkinson's monitoring technology into consumer wearables, while One Health Group beat earnings expectations as construction work began on a new surgical hub.
Frontier IP portfolio company wins EU grant for Parkinson's wearable algorithms
inSignals Neurotech, a portfolio company of Frontier IP Group (AIM:FIPP), secured a European Union grant to extend its proprietary Parkinson's disease monitoring algorithms beyond specialist clinical settings and into everyday consumer wearable devices. The award marks a meaningful step in the commercialisation of technology developed within the academic spinout ecosystem that Frontier IP supports. Co-founder and chief science officer João Paulo Cunha described the funding as enabling the company to bring its algorithms to a far broader patient population.
Frontier IP shares rose 14.3% to 16.0p on the news, reflecting the market's view of the grant as a material de-risking event for one of the group's key portfolio holdings.
One Health Group beats EBITDA expectations as surgical hub build begins
One Health Group (AIM:OHGR) reported results ahead of EBITDA expectations and confirmed that construction has started on a new surgical hub, reinforcing its capacity to absorb growing NHS referral volumes. The group positioned itself as a provider of local, free-at-point-of-use healthcare for NHS commissioners and patients, with the new facility expected to expand throughput as demand from the health service continues to build.
The shares added 3.5% to 251.0p, with investors responding positively to both the earnings beat and the tangible progress on infrastructure expansion.
